The Prevalence of Prostate Carcinoma and Its Precursor in Hungary: An Autopsy Study

Soós, Györgyike; Tsakiris, Ioannis; Szántó, J.; Turzo, Csaba; Haas, Phillippe; Dezső, Balázs

doi:10.1016/j.eururo.2005.08.010

Cited by 90 publications

(60 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the progression phase of carcinogenesis in vivo, foci of transformed cells, in the absence of the ability to induce angiogenesis, are generally limited to small foci a few millimeters in diameter (32). Hyperplastic foci without apparent angiogenic potential are often found at autopsy in many tissues, such as the prostate (33).…”

Section: Discussionmentioning

confidence: 99%

The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent

Vannini

Lorusso

Cammarota

et al. 2007

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

We show that the synthetic oleanane triterpenoid, CDDOmethyl ester (CDDO-Me; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate) is an effective agent for suppressing angiogenesis, both in cell culture and in vivo. The potency of CDDO-Me is particularly striking when dosed in vivo to inhibit the angiogenic effects of vascular endothelial growth factor and tumor necrosis factor-A in Matrigel sponge assays; activity is seen at i.p. doses of CDDO-Me as low as 0.003 mg/kg of body weight. If the Matrigel sponges are impregnated with CDDO-Me just before implantation in the mice, picomolar doses of CDDO-Me will suppress angiogenesis. CDDO-Me also inhibits growth of endothelial cells in monolayer cultures and suppresses neovascular morphogenesis in three-dimensional cultures, but significantly higher doses (50-200 nmol/L) are required. We also show antiangiogenic effects of CDDOMe on xenografts of Kaposi's sarcoma cells in immunocompromised mice, using CD31 as a marker. Several known individual molecular targets of CDDO-Me and related triterpenoids that are relevant to all of these findings include nuclear factor-KB signaling, signal transducers and activators of transcription signaling, and transforming growth factor-B signaling, as well as Keap1, the endogenous inhibitor of the transcription factor Nrf2. However, the particularly potent antiangiogenic activity seen in vivo in the present experiments suggest that CDDO-Me, as an angioprevention agent, may be interacting with an entire network of molecular and cellular targets, rather than at a single molecular locus or in a single-cell type.

show abstract

Section: Discussionmentioning

confidence: 99%

The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent

Vannini

Lorusso

Cammarota

et al. 2007

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…The distribution of both histological and clinical PC differs among races (10). Regarding men of Caucasian origin, the incidence of histologically confirmed lesions seems to be significantly lower in Mediterranean male populations compared to the incidence in northern European males (11,12). PC mortality rates seem that present similar curves to those of PC incidence worldwide.…”

Section: Discussionmentioning

confidence: 48%

“Is Prostate Cancer Screening Worthy in Southern European Male Populations? A Case Study in Eleusina, Greece: Prostate Cancer Screening in Eleusina

et al. 2012

View full text Add to dashboard Cite

“…Although prostate cancer can be slow growing, the disease nonetheless accounts for 10% of cancer-related deaths in males and 13% of all deaths [2,3], with thousands of men dying of prostate cancer each year. In Cameroon, the burden is still very high and the result published by WHO in May 2014 shows a death rate of 2,366/100000 males and ranking Cameroon as the 43rd nation with high mortality in the world [4]. Global Burden of cancer (GLOBOCAN) statistics for 2008 reveals that about 169.3 million healthy lives were lost worldwide due to cancers, including cancer of the prostate which was responsible for over 4.041 million deaths worldwide, increasing mortality rate due to prostate cancer occur in countries like the Republic of Korea with mortality rates of 7.6%, Moldova 6.5%, Trinidad 4.7%.…”

Section: Introductionmentioning

confidence: 99%

“…Following a research conducted by Jackson and his coworkers [6] the prevalence of prostate cancer in several African countries increases up to 50 folds. Considering the 2013 report from WHO, Africa had the lowest Growth National Income of 2513 US Dollars with 49.2 Dollars spent on cancer yearly; indicating the burden this disease has on the economy of this continent.…”

Section: Introductionmentioning

confidence: 99%

A Discrete Choice Clinical Survey and a Proposed Health Promotion Framework for Prostate Cancer in Cameroon

Anchang¹,

Tetuh²,

Nji³

et al. 2017

Can Res

View full text Add to dashboard Cite

Background: Due to the dearth of information about the burden of prostate cancer disease in Cameroon, and in respond to the Sustainable Development Goal (SDG#3) to prevent non-communicable diseases, a discrete choice clinical study of prostate cancer with the aim to determine the incidence, the associated risk factors and comparative diagnostic tools among males in the NorthWest region of Cameroon was undertaken.

show abstract

The Prevalence of Prostate Carcinoma and Its Precursor in Hungary: An Autopsy Study

Cited by 90 publications

References 30 publications

The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent

The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent

“Is Prostate Cancer Screening Worthy in Southern European Male Populations? A Case Study in Eleusina, Greece: Prostate Cancer Screening in Eleusina

A Discrete Choice Clinical Survey and a Proposed Health Promotion Framework for Prostate Cancer in Cameroon

Contact Info

Product

Resources

About